Tyra Bioscience (TYRA)
NASDAQ:TYRA
Top Page
Tyra Bioscience
(NASDAQ:TYRA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$36.00
▲(2.95% Upside)
Action:ReiteratedDate:04/03/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and increasing cash burn), partially offset by strong technical momentum (price above major moving averages with positive MACD) and supportive corporate events (notably the $126M equity raise). Valuation remains difficult to assess due to negative earnings and no dividend data.
Positive Factors
Proprietary SNÅP platform and FGFR-focused pipeline
Tyra’s SNÅP discovery platform and focused FGFR inhibitor pipeline supply a durable scientific moat: systematic mutation profiling increases odds of finding clinically relevant resistance mechanisms and designing differentiated molecules. That platform-driven approach supports pipeline productivity, partner interest, and long-term drug development optionality.
Negative Factors
Pre-revenue with widening net losses
Being pre-revenue with materially widening losses is a persistent fundamental constraint: ongoing negative margins consume equity, prolong dependence on external funding, and mean commercialization economics remain unproven. Absent clinical milestone success, losses could continue to accelerate over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary SNÅP platform and FGFR-focused pipeline
Tyra’s SNÅP discovery platform and focused FGFR inhibitor pipeline supply a durable scientific moat: systematic mutation profiling increases odds of finding clinically relevant resistance mechanisms and designing differentiated molecules. That platform-driven approach supports pipeline productivity, partner interest, and long-term drug development optionality.
Read all positive factors
Tyra Bioscience (TYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.88B
Dividend YieldN/A
Average Volume (3M)370.94K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue GrowthN/A
EPS Growth-17.01%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding53,867,115
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.64K
Enterprise Value/Ebitda-15.13
Forecast
1Y Price Target
$51.00Price Target Upside45.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.38
Revenue Forecast (FY)N/A
Tyra Bioscience Business Overview & Revenue Model
Company Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fib...
How the Company Makes Money
Tyra Biosciences does not primarily generate revenue from product sales because it is a clinical-stage company without approved commercial products. Its earnings have historically depended on external financing and, where applicable, collaboration...
Tyra Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -546.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -119.40M | -103.66M | -79.59M | -58.63M | -26.15M |
| Net Income | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
Balance Sheet | |||||
| Total Assets | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M |
| Cash, Cash Equivalents and Short-Term Investments | 256.00M | 341.44M | 203.47M | 251.21M | 302.18M |
| Total Debt | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M |
| Total Liabilities | 23.43M | 20.41M | 21.59M | 8.35M | 4.96M |
| Stockholders Equity | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
Cash Flow | |||||
| Free Cash Flow | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M |
| Operating Cash Flow | -95.14M | -69.77M | -50.14M | -50.28M | -23.75M |
| Investing Cash Flow | 72.46M | -98.40M | -144.60M | -559.00K | -645.00K |
| Financing Cash Flow | 8.10M | 202.14M | 1.54M | 632.00K | 311.35M |
Tyra Bioscience Technical Analysis
Neutral
34.97
Price Trends
34.39
Positive
29.89
Positive
21.17
Positive
Market Momentum
0.42
Positive
46.42
Neutral
12.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Neutral. The current price of 34.97 is below the 20-day moving average (MA) of 37.13, above the 50-day MA of 34.39, and above the 200-day MA of 21.17, indicating a neutral trend. The MACD of 0.42 indicates Positive momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 12.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TYRA.
Tyra Bioscience Risk Analysis
Tyra Bioscience disclosed 87 risk factors in its most recent earnings report. Tyra Bioscience reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tyra Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.08B | -39.12 | -20.02% | ― | ― | 12.45% | |
57 Neutral | $1.84B | -28.23 | -98.14% | ― | ― | ― | |
55 Neutral | $1.88B | -13.06 | -34.75% | ― | ― | -17.01% | |
54 Neutral | $1.07B | -37.98 | -444.41% | ― | ― | -13.14% | |
53 Neutral | $1.75B | -5.04 | -64.21% | ― | 48.32% | -1.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $105.82M | -3.72 | 264.70% | ― | -58.17% | -116.24% |
* Healthcare Sector Average
TYRA
Tyra Bioscience
34.97
26.36
306.16%
KALV
KalVista Pharmaceuticals
20.86
9.12
77.61%
PVLA
Palvella Therapeutics
128.63
104.23
427.17%
GOSS
Gossamer Bio
0.45
-0.38
-45.78%
NRIX
Nurix Therapeutics
16.97
7.17
73.16%
TERN
Terns Pharmaceuticals
52.71
50.47
2253.12%
Tyra Bioscience Corporate Events
Executive/Board Changes
Tyra Bioscience Strengthens Financial Leadership with New Officer
Positive
Apr 2, 2026
On April 1, 2026, Tyra Biosciences, Inc. appointed Vice President of Finance Julia Rueb as its principal accounting officer, succeeding Chief Financial Officer Alan Fuhrman in that specific role while he remains the company’s principal finan...
Private Placements and FinancingRegulatory Filings and Compliance
Tyra Bioscience Raises $126 Million in Block Share Sale
Positive
Mar 4, 2026
On March 4, 2026, Tyra Biosciences, Inc. agreed to issue and sell 4,000,000 shares of its common stock to a large investment management firm at $31.50 per share, in a block transaction under its existing at-the-market equity offering program. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.